An open label multi facilities cooperation randomized control trial to verify urinary angiotensinogen excretion reducing effect of olmesartan therapy in diabetic nephropathy.

An open label multi facilities cooperation randomized control trial to verify urinary angiotensinogen excretion reducing effect of olmesartan therapy in diabetic nephropathy. - Olmesartan Reduces urinary Inflammatiory and Oxidative stress markers in Diabetic Nephropathy, with suppressing urinary Angiotensinogen elevation. ORION-Angel Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001618

Enrollment

100

Registered

2009-03-09

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive type2 diabetic nephropathy patients with chronic kidney disease (CKD)

Interventions

This Study is a prospective randomized control trial. The entry period of this study is one year. Subjects are hypertensive diabetic nephropathy, who has not been taken RAS inhibitors. The patients ar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects enrolled in the present study are hypertensive type 2 diabetic outpatients with nephropathy, who visit our hospitals and fulfilled the following criteria: 1) mild or moderate hypertension (blood pressure 130-200/90-110 mmHg) 2) mild or moderate hyperglycemia (HbA1c < 8%) 3) an urinary albumin excretion higher than 30 mg/g creatinine.

Exclusion criteria

Exclusion criteria: 1) A serum creatinine level is more than 2.5 mg/dl and existence of hematuria. 2) A patient who has received continuous dialysis. 3) With severe diabetic complications such as retinal hemorrhage, neuropathy, and so on. 4) Existence of severe hepatic damages, and cerebrovascular disorders including heart failure. 5) A severe hypertensive patient (BP > 200/110 mmHg). 6) Use of rennin angiotensin system (RAS) inhibitors.

Design outcomes

Primary

Measure	Time frame
Changes of urinary angiotensinogen excretion, monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, 8-epi prostaglandin F2alpha 8-hydroxydeoxyguanosine, albumin excretion (albumin to creatinine ratio: ACR) and blood pressure.	—

Countries

Japan

Contacts

Public ContactSusumu Ogawa

Tohoku University Hospital Division of Nephrology, Endocrinology and Hypertension

ogawa-s@hosp.tohoku.ac.jp022-717-7166

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026